0001193125-24-199384 | 6-K | XBRL Viewer

Revenue from collaboration agreements

5. Revenue from collaboration agreements

The Group currently earns revenue through strategic collaboration agreements with third party pharmaceutical and biotechnology companies. As of June 30, 2024, the Group had four revenue-generating strategic collaboration agreements in place, three with Bristol-Myers-Squibb (“BMS”) and

one

agreement with ModernaTX, Inc. (“Moderna”), effective in October 2023. Three of the four revenue-generating strategic collaboration agreements are in

pre-clinical

stage and the BMS IMA401 collaboration agreement is in clinical stage. The collaboration with Genmab A/S, Copenhagen /Denmark (“Genmab”) was terminated in March 2024 and the Group recorded the remaining deferred revenue of €14.9 million from the Genmab collaboration during the three months ended March 31, 2024.

Revenue from collaboration agreements was realized with the following partners:


	Three months ended June 30,				Six months ended June 30,
	2024		2023		2024		2023
	(Euros in thousands)				(Euros in thousands)
BMS, United States		10,035		21,439		15,770		31,935
Moderna, United States		8,720		—		18,303		—
Genmab, Denmark		—		915		14,951		215

Total		18,755		22,354		49,024		32,150

As of June 30, 2024, the Group has not recognized any milestone revenue under the collaboration agreements, due to the scientific uncertainty of achieving the milestones or the successful commercialization of a product. As of June 30, 2024, Immatics had not received any milestone or royalty payments in connection with the collaboration agreements. The Group plans to recognize the remaining deferred revenue balance into revenue as it performs the related performance obligations under each contract.

The revenue for the three and six months ended June 30, 2024 from collaboration agreements with BMS and Moderna is revenue recognized over time on a cost-to-cost basis. For the collaboration with BMS the revenue for

the

three and six months ended June 30, 2023 included an

Opt-in

payment of €13.7 million compared to the three and six months ended June 30, 2024. The collaboration with Moderna is effective since October 2023, therefore no revenue is recognized during the three and six months ended June 30, 2023. For the three months ended June 30, 2024 no revenue was recognized for the collaboration with Genmab as the collaboration was terminated in March 2024

. The termination resulted

in a recognition of the remaining deferred revenue of €14.9 million during the six months ended June 30, 2024.

Deferred revenue related to the collaboration agreements consists of the following:


	As of
	June 30, 2024		December 31, 2023
	(Euros in thousands)
Current		95,521		100,401
Non-current		75,298		115,527

Total		170,819		215,928

Deferred revenues are contract liabilities within the scope of IFRS 15.

The Group recognized expenses related to the amortization of capitalized cost of obtaining a contract of €0.4 million and €0.1 million for the six months ended June 30, 2024 and June 30, 2023.

Earnings and Loss per Share - Summary of Earnings and Loss per Share (Detail) - EUR (€) € / shares in Units, € in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Earnings per share [abstract]
Net profit/(loss)	€ (18,022)	€ (24,610)	€ (21,076)	€ (44,357)
Basic	€ (0.17)	€ (0.32)	€ (0.21)	€ (0.58)
Diluted	€ (0.17)	€ (0.32)	€ (0.21)	€ (0.58)
Weighted average shares outstanding:
Basic	103,071,657	77,311,053	100,917,905	76,994,713
Diluted	103,071,657	77,311,053	100,917,905	76,994,713

The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 7
-IssueDate 2023-01-01
-Paragraph 18
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_18_b&doctype=Standard
-URIDate 2023-03-23

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2023-01-01
-Paragraph 32
-Subparagraph a
-Clause ii
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_ii&doctype=Standard
-URIDate 2023-03-23

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2023-01-01
-Paragraph 24
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_b&doctype=Standard
-URIDate 2023-03-23

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2023-01-01
-Paragraph 28
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard
-URIDate 2023-03-23

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2023-01-01
-Paragraph 23
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard
-URIDate 2023-03-23

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2023-01-01
-Paragraph B10
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B
-URIDate 2023-03-23

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 17
-IssueDate 2023-01-01
-Paragraph 113
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_113_b&doctype=Standard
-URIDate 2023-03-23

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2023-01-01
-Paragraph 81A
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_a&doctype=Standard
-URIDate 2023-03-23

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2023-01-01
-Paragraph 106
-Subparagraph d
-Clause i
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_i&doctype=Standard
-URIDate 2023-03-23

+ Details

Cover Page	6 Months Ended
Cover Page	Jun. 30, 2024
Document Information [Line Items]
Document Type	6-K
Amendment Flag	false
Document Period End Date	Jun. 30, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Entity Registrant Name	IMMATICS N.V.
Entity Central Index Key	0001809196
Current Fiscal Year End Date	--12-31

Financial result - Additional Information (Detail) € / shares in Units, € in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024 EUR (€) € / shares	Jun. 30, 2023 EUR (€) € / shares	Jun. 30, 2024 EUR (€) € / shares	Jun. 30, 2023 EUR (€) € / shares	Jun. 30, 2024 $ / shares	Mar. 31, 2024 € / shares	Mar. 31, 2024 $ / shares	Dec. 31, 2023 € / shares	Dec. 31, 2023 $ / shares	Jun. 30, 2023 $ / shares	Mar. 31, 2023 € / shares	Mar. 31, 2023 $ / shares	Dec. 31, 2022 € / shares	Dec. 31, 2022 $ / shares
Statements [Line Items]
Change in fair value of warrant liabilities	€ 0.6	€ 13.1	€ 0.4	€ 5.7
Top of range [member]
Statements [Line Items]
Exercise price of warrants or rights \| (per share)	€ 2.59	€ 3.15	€ 2.59	€ 3.15	$ 2.77					$ 3.42
Bottom of range [member]
Statements [Line Items]
Exercise price of warrants or rights \| (per share)						€ 2.5	$ 2.7	€ 2.64	$ 2.92		€ 1.32	$ 1.44	€ 2.35	$ 2.51

Earnings and Loss per Share - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2024 shares
Text Block [Abstract]
Dilutive effect of share options on number of warrants	7,187,500

Financial result - Summary of financial income and financial expenses (Detail) - EUR (€) € in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Disclosure Of Detailed Information About Finance Income Expense [Abstract]
Change in fair value of liabilities for warrants	€ (648)	€ (13,105)	€ 395	€ (5,708)
Interest income	6,366	2,744	12,659	4,999
Foreign currency gains	2,763	1,210	7,851	1,749
Gain on other financial instruments	536	0	70	0
Other financial income	9,665	3,954	20,580	6,748
Interest expenses	(226)	(206)	(420)	(401)
Foreign currency losses	(79)	(805)	(95)	(4,119)
Losses on financial instruments	0	(133)	0	(133)
Other financial income	(305)	(1,144)	(515)	(4,653)
Financial result	€ 8,712	€ (10,295)	€ 20,460	€ (3,613)

Income Tax	6 Months Ended
Income Tax	Jun. 30, 2024
Text Block [Abstract]
Income Tax	7. Income Tax During the three and six months ended June 30, 2024, Immatics N.V. and Immatics US Inc. generated a net loss within the Group. Immatics GmbH generated a net income for the three months ended June 30, 2024 due to the recognition of revenue from the collaboration agreements with BMS and Moderna and correspondingly the Group recognized an income tax expense of €0.2 million and an equivalent current tax liability. For the six months ended June 30, 2024, Immatics GmbH generated a net income due to the recognition of the remaining upfront payment of €14.9 million within revenue, in connection with the termination of the collaboration with Genmab and revenue from collaboration agreements, correspondingly the Group recognized an income tax expense of €1.5 million and an equivalent current tax liability. The income tax expense is calculated based on taxable income of Immatics GmbH for the three and six months ended June 30, 2024 and does not take into account any potential income or loss of the following quarter. The Group applied the estimated effective tax rate for the financial year 2024 to the taxable income for the three and six months ended June 30, 2024. T he Group took into account the tax losses carried forward that can be used to offset the taxable income generated in the three and six months ended June 30, 2024 for the purpose of income tax calculation. In accordance with § 10d para 2 EStG (German income tax code), 70% (corporate tax) / 60% (trade tax) of an income of a given year can be offset with tax losses carried forward. Accordingly, 30% / 40% of the income before tax of Immatics GmbH is subject to income tax. As the profit generated by Immatics GmbH during the three and six months ended June 30, 2024 is considered as a one-time profit, no deferred tax assets exceeding the deferred tax liability for temporary differences have been recognized in respect of tax losses carried forward. The current assessment regarding the usability of deferred tax assets may change, depending on the Group’s taxable income in future years, which could result in the recognition of deferred tax assets. The Group generated losses for all entities within the Group during the three and six months ended June 30, 2023. During the three and six months ended June 30, 2024 and 2023, the Group’s German operations were subject to a statutory tax rate of 30.4% and the Group’s U.S. operations were subject to a federal corporate income tax rate of 21%. Due to changes in ownership in prior periods, there are certain limitations on tax losses carried forward for net operating losses incurred by Immatics US, Inc., under Section 382 of the U.S. Internal Revenue Code.

Property, plant and equipment, intangible assets and Right-of-use assets	6 Months Ended
	Jun. 30, 2024
Text Block [Abstract]
Property, plant and equipment, intangible assets and Right-of-use assets	10. Property, plant and equipment, intangible assets and Right-of-use assets During the three months ended June 30, 2024 and June 30, 2023, the Group acquired property, plant and equipment and intangible assets in the amount of €2.2 million and €11.6 million, respectively. During the six months ended June 30, 2024 and June 30, 2023, the Group acquired property, plant and equipment and intangible assets in the amount of €9.7 million and €15.7 million, respectively. The Group’s additions include leasehold improvements, lab equipment, office equipment and computer equipment for the research and commercial GMP manufacturing facility construction in Houston, Texas of €6.3 million for the six months ended June 30, 2024. During the three months ended June 30, 2024, there was an addition of €2.4 million in right-of-use assets and corresponding lease liability for the new research facility in Tübingen, Germany. Further, modifications of right-of-use assets resulted in an increase of €1.2 million.

Segment information	6 Months Ended
Segment information	Jun. 30, 2024
Text Block [Abstract]
Segment information	4. Segment information The Group manages its operations as a single segment for the purpose of assessing performance and making operating decisions. The Group’s focus is on the research and development of T cell redirecting immunotherapies for the treatment of cancer. The Chief Executive Officer is the chief operating decision maker who regularly reviews the consolidated operating results and makes decisions about the allocation of the Group’s resources.

Earnings and Loss per Share

6 Months Ended

Jun. 30, 2024

Earnings and Loss per Share

17. Earnings and Loss per Share

The Group reported basic and diluted loss per share during the three and six months ended June 30, 2024 and 2023. Basic earnings and loss per share are calculated by dividing the net profit or loss by the weighted-average number of ordinary shares outstanding for the reporting period. Diluted earnings and loss per share, are calculated by adjusting the weighted-average number of ordinary shares outstanding for any dilutive effects resulting from equity awards granted to the Board and employees of the Group as well as from publicly traded Immatics Warrants. The

Group’s

equity awards and Immatics Warrants for which the exercise price is exceeding the Group’s weighted average share price, are excluded in the calculation of diluted weighted average number of ordinary shares.

The Group was loss-making during the three and six months ended June 30, 2024 and during the three and six months ended June 30, 2023, therefore all instruments under the 2020 and 2022 Equity Plan are anti-dilutive instruments and are excluded in the calculation of diluted weighted average number of ordinary shares outstanding. The 7,187,500 Immatics Warrants issued in 2020 and outstanding as of June 30, 2024 have no dilutive effect for the three months ended June 30, 2024 and 2023 and the six months ended June 30, 2023 as the Group’s weighted average share price is below the exercise price for the given period. For the six months ended June 30, 2024 the Immatics Warrants are anti-dilutive as their conversion to ordinary shares would have decreased loss per share.


	Three months ended June 30,						Six months ended June 30,
	2024			2023			2024			2023
	(Euros in thousands, except share and per share data)						(Euros in thousands, except share and per share data)
Net loss		(18,022	)		(24,610	)		(21,076	)		(44,357	)
Basic		(0.17	)		(0.32	)		(0.21	)		(0.58	)
Diluted		(0.17	)		(0.32	)		(0.21	)		(0.58	)
Weighted average shares outstanding:
Basic		103,071,657			77,311,053			100,917,905			76,994,713
Diluted		103,071,657			77,311,053			100,917,905			76,994,713

Share-based payments - Summary of Employee Related Share Based Compensation Expense (Detail) - EUR (€) € in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Disclosure Of Detailed Information About Share Based Compensation Expense [Line Items]
Share-based compensation expense	€ (4,308)	€ (5,513)	€ (8,605)	€ (11,615)
Research And Development Expense [Member]
Disclosure Of Detailed Information About Share Based Compensation Expense [Line Items]
Share-based compensation expense	(2,595)	(3,282)	(4,863)	(6,815)
General And Administrative Expense [Member]
Disclosure Of Detailed Information About Share Based Compensation Expense [Line Items]
Share-based compensation expense	€ (1,713)	€ (2,231)	€ (3,742)	€ (4,800)

Revenue from collaboration agreements - Summary of revenue from collaboration agreements (Detail) - EUR (€) € in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Disclosure Of Revenue From Collaboration Agreements [Line Items]
Revenue from collaboration agreements	€ 18,755	€ 22,354	€ 49,024	€ 32,150
Genmab [Member]
Disclosure Of Revenue From Collaboration Agreements [Line Items]
Revenue from collaboration agreements			14,900
Denmark [Member] \| Genmab [Member]
Disclosure Of Revenue From Collaboration Agreements [Line Items]
Revenue from collaboration agreements	0	915	14,951	215
United States [Member] \| Moderna [Member]
Disclosure Of Revenue From Collaboration Agreements [Line Items]
Revenue from collaboration agreements	8,720	0	18,303	0
United States [Member] \| BMS [Member]
Disclosure Of Revenue From Collaboration Agreements [Line Items]
Revenue from collaboration agreements	€ 10,035	€ 21,439	€ 15,770	€ 31,935

Condensed Consolidated Statement of Cash Flows of Immatics N.V. € in Thousands, $ in Thousands	6 Months Ended
	Jun. 30, 2024 EUR (€)	Jun. 30, 2023 EUR (€)
Cash flows from operating activities
Net loss	€ (21,076)	€ (44,357)
Taxes on income	1,503	0
Loss before tax	(19,573)	(44,357)
Adjustments for:
Interest income	(12,660)	(4,999)
Depreciation and amortization	6,116	3,666
Interest expenses	420	401
Equity-settled share-based payment	8,605	11,615
Loss from disposal of fixed assets	1	0
Net foreign exchange differences and expected credit losses	(7,723)	4,081
Change in fair value of liabilities for warrants	(395)	5,708
Changes in:
Decrease in accounts receivables	1,283	781
Decrease/(increase) in other assets	(1,246)	765
(Decrease) in deferred revenue, accounts payables and other liabilities	(48,493)	(9,889)
Interest received	8,260	2,051
Interest paid	(420)	(146)
Income tax paid	0	0
Net cash used in operating activities	(65,825)	(30,323)
Cash flows from investing activities
Payments for property, plant and equipment	(11,797)	(15,004)
Payments for intangible assets	(148)	(154)
Payments for investments classified in other financial assets	(356,596)	(170,326)
Proceeds from maturity of investments classified in other financial assets	196,548	164,929
Net cash used in investing activities	(171,993)	(20,555)
Cash flows from financing activities
Proceeds from issuance of shares to equity holders	174,476	38,608
Transaction costs deducted from equity	0	(1,157)
Repayments related to lease liabilities	(397)	(1,866)
Net cash provided by financing activities	174,079	35,585
Net decrease in cash and cash equivalents	(63,739)	(15,293)
Cash and cash equivalents at beginning of the year	218,472	148,519
Effects of exchange rate changes and expected credit losses on cash and cash equivalents	3,410	(2,821)
Cash and cash equivalents at end of the year	€ 158,143	€ 130,405

Accounts payable (Tables)

6 Months Ended

Jun. 30, 2024

Summary of Accounts Payable

Accounts payables consist of the following:


	As of
	June 30, 2024		December 31, 2023
	(Euros in thousands)
Accounts payables		3,800		7,666
Accrued liabilities		14,991		17,540

Total		18,791		25,206

Revenue from collaboration agreements - Summary of Deferred revenue related to the collaboration agreements (Detail) - EUR (€) € in Thousands	Jun. 30, 2024	Dec. 31, 2023
Revenue [abstract]
Current	€ 95,521	€ 100,401
Non-current	75,298	115,527
Total	€ 170,819	€ 215,928

Provisions - Summary of Provisions (Detail) - EUR (€) € in Thousands	Jun. 30, 2024	Dec. 31, 2023
Provisions [abstract]
Provision for bonuses	€ 3,437	€ 0
Total	€ 3,437	€ 0

Significant events and changes in the current reporting period	6 Months Ended
	Jun. 30, 2024
Text Block [Abstract]
Disclosure of changes in accounting policies, accounting estimates and errors [text block]	2. Significant events and changes in the current reporting period The following significant events or transactions occurred during the three and six months ended June 30, 2024. On January 22, 2024, the Group closed an offering of 18,313,750 ordinary shares with a public offering price of $11.00 per ordinary share. The Group received gross proceeds of €185.0 million less transaction costs of €11.5 million, resulting in an increase in share capital of €183 thousand and share premium of €173.3 million. Macroeconomic environment Currently, multiple global uncertainties are existing. The conflict between Russia and Ukraine and the Palestinian-Israeli conflict have resulted, and may further result, in significant disruption, instability and volatility in global markets, as well as higher energy and other commodity prices. Since the Company is not currently conducting any business or receiving any material services from vendors located in Russia, Ukraine or Israel, it does not expect that the ongoing conflicts will have a direct impact on its operations in the near term. However, the Company may be indirectly affected by price increases or certain policy changes, such as new tax legislation, economic sanctions and comparable measures. While the conflicts are currently not expected to have a direct impact on the Company, this may change in case of further expansion of the scale of the conflicts. In addition, other geopolitical instabilities might impact the Group in the future.

Share-based payments - Additional Information (Detail) $ / shares in Units, € in Millions, $ in Billions			6 Months Ended
	Feb. 07, 2024 $ / shares	Jul. 01, 2020 EUR (€) $ / shares	Jun. 30, 2024 USD ($) shares $ / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share based compensation by share based payment arrangement fair value per share			$ 9.34
Performance Based Options [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average share price of share options granted	$ 11.15
Performance Based Options [Member] \| Tranche One [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Minimum market capitalization \| $			$ 1.5
Performance Based Options [Member] \| Tranche Two [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Minimum market capitalization \| $			2.0
Performance Based Options [Member] \| Tranche Three [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Minimum market capitalization \| $			$ 3.0
Performance Based Options [Member] \| Granted On September 2021 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share based compensation by share based payment arrangement fair value per share	$ 6.37
Matching Stock Options [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share based compensation by share based payment arrangement exercise price per share granted			$ 10
Share based compensation by share based payment arrangement term of stock options			10
Date of vesting of stock options			Jul. 31, 2021
Modification Of Awards Under Two Thousand Ten And Two Thousand And Sixteen Plan [Member] \| Share Reinvestment [Member] \| Matching Stock Options [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share based compensation by share based payment arrangement term of stock options			10
Date of vesting of stock options			Jul. 31, 2021
Modification Of Two Thousand And Sixteen Plan [Member] \| Share Reinvestment [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share based compensation by share based payment arrangement options granted during the period \| shares			733,598
Fair value of stock appreciation rights \| €		€ 8.5
Weighted average share price of share options granted		€ 15.15
Modification Of Two Thousand And Sixteen Plan [Member] \| Share Reinvestment [Member] \| Matching Stock Options [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share based compensation by share based payment arrangement exercise price per share granted			$ 10

Accounts payable

6 Months Ended

Jun. 30, 2024

Summary of Earnings and loss per share

Accounts payable

12. Accounts payables

Accounts payables consist of the following:


	As of
	June 30, 2024		December 31, 2023
	(Euros in thousands)
Accounts payables		3,800		7,666
Accrued liabilities		14,991		17,540

Total		18,791		25,206

Condensed Consolidated Statement of Financial Position of Immatics N.V. - EUR (€) € in Thousands	Jun. 30, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	€ 158,143	€ 218,472
Other financial assets	372,964	207,423
Accounts receivables	2,811	4,093
Other current assets	25,200	19,382
Total current assets	559,118	449,370
Non-current assets
Property, plant and equipment	50,289	43,747
Intangible assets	1,608	1,523
Right-of-use assets	14,616	13,308
Other non-current assets	1,336	2,017
Total non-current assets	67,849	60,595
Total assets	626,967	509,965
Current liabilities
Provisions	3,437	0
Accounts payables	18,791	25,206
Deferred revenue	95,521	100,401
Liabilities for warrants	18,598	18,993
Lease liabilities	3,178	2,604
Other current liabilities	10,021	9,348
Total current liabilities	149,546	156,552
Non-current liabilities
Deferred revenue	75,298	115,527
Lease liabilities	14,235	12,798
Other non-current liabilities	0	4
Total non-current liabilities	89,533	128,329
Shareholders' equity
Share capital	1,031	847
Share premium	1,006,064	823,166
Accumulated deficit	(618,369)	(597,293)
Other reserves	(838)	(1,636)
Total shareholders' equity	387,888	225,084
Total liabilities and shareholders' equity	€ 626,967	€ 509,965

Earnings and Loss per Share (Tables)

6 Months Ended

Jun. 30, 2024

Earnings per share [abstract]


	Three months ended June 30,						Six months ended June 30,
	2024			2023			2024			2023
	(Euros in thousands, except share and per share data)						(Euros in thousands, except share and per share data)
Net loss		(18,022	)		(24,610	)		(21,076	)		(44,357	)
Basic		(0.17	)		(0.32	)		(0.21	)		(0.58	)
Diluted		(0.17	)		(0.32	)		(0.21	)		(0.58	)
Weighted average shares outstanding:
Basic		103,071,657			77,311,053			100,917,905			76,994,713
Diluted		103,071,657			77,311,053			100,917,905			76,994,713

Share-based payments

6 Months Ended

Jun. 30, 2024

Share-based payments

8. Share-based payments

Immatics N.V. has three share-based payment plans. In June 2020, Immatics N.V. established an initial equity incentive plan (“2020 Equity Plan”). This plan was complemented by the Company’s 2022 stock option and incentive plan (“2022 Equity Plan”) which was approved by the Immatics shareholders at the Annual General Meeting on June 13, 2022. At the Annual General Meeting on June 20, 2024, Immatics shareholders approved the Company’s 2024 stock option and incentive plan (“2024 Equity Plan”). The 2024 Equity Plan allows the company to grant additional options.

Immatics GmbH previously issued share-based awards to employees under two different plans. Under the GmbH Stock Appreciation Program 2010 (the “2010 Plan”), the Company issued stock appreciation rights (“SARs”), which the Group accounted for as cash-settled awards. Under the Immatics GmbH 2016 Equity Incentive Plan (“2016 Plan”), the Company issued tandem awards, which contained the possibility to function as either a SAR or a stock option. The Group accounted for awards issued under the 2016 Plan, which were redeemable in either cash or equity shares at the Group’s discretion, as equity-settled.

As part of the ARYA Merger, all outstanding awards under the 2010 Plan and 2016 Plan were replaced by a combination of cash payments and share-based awards under the 2020 Equity Plan in Immatics N.V. Under the 2020 Equity Plan, management and employees have been granted different types of options, all of which are equity-settled transactions. As part of the replacement, active employees and management members received stock options (“Matching Stock Options”) to acquire shares in Immatics N.V. The Matching Stock Options have an exercise price of $10.00 and vested in full on July 31, 2021. The awards have a

10-year

contract life.

Share-based Awards

The share-based awards, that were received by employees as part of the conversion, consisted of

Re-investment

Shares, Matching Stock Options and Converted Stock Options as described below.

In accordance with the employee

re-investment

elections, employees received 733,598 shares in Immatics N.V.

(“Re-investment

Shares”), which had a fair value of €8.5 million based on the ARYA share price of $15.15, as of the merger on July 1, 2020. The

Re-investment

Shares issued represented a modification of awards previously granted under the 2010 Plan and the 2016 Plan. For each ordinary

Re-investment

Share received, active employees and management members also received two stock options (“Matching Stock Options”) to acquire shares in Immatics N.V. The Matching Stock Options have an exercise price of $10.00 and vested in full on July 31, 2021. The award recipient must remain employed by Immatics or one of its affiliates through the vesting date, to receive the option. The awards have a

10-year

contract life.

Matching Stock Options outstanding as of June 30, 2024:


	2024
	Weighted average exercise price in USD		Number
Matching Stock Options outstanding on January 1		10.00		1,342,648
Matching Stock Options forfeited		—		—
Matching Stock Options exercised		10.00		21,748
Matching Stock Options expired		—		—
Matching Stock Options outstanding on June 30		10.00		1,320,900
Matching Stock Options exercisable on June 30		10.00		1,320,900
Weighted average remaining contract life (years)		6.00

For any outstanding 2016 Plan and 2010 Plan awards scheduled to vest on or after January 1, 2021, employees received replacement stock options (“Converted Options”) to acquire shares in Immatics N.V. The Converted Options have comparable terms as the previous awards, with revised exercise prices reflecting the reorganized capital structure of Immatics. The options granted under the 2020 Equity Plan that gives employees the right to acquire shares in Immatics N.V. are accounted for as a modification under IFRS 2, with the incremental fair value expensed over the remaining vesting period.

The incremental fair value is the difference between the fair value of the options to purchase ordinary shares under the 2020 Equity Plan to acquire shares in Immatics N.V. and the fair value of the exchanged unvested SAR (both measured at the date on which the replacement award is issued).

Converted Options outstanding as of June 30, 2024:


	2024
	Weighted average exercise price in USD		Number
Converted Options outstanding on January 1		2.81		503,310
Converted Options forfeited		—		—
Converted Options exercised		1.22		23,207
Converted Options expired		—		—
Converted Options outstanding on June 30		2.89		480,103
Converted Options exercisable on June 30		2.89		480,103
Weighted average remaining contract life (years)		3.51

Additional grants under the 2020 and 2022 Equity Plan

Service Options

Under the 2020 Equity Plan and the 2022 Equity Plan, Immatics also issues employee stock options with a service requirement (“Service Options”) to acquire shares of Immatics N.V. The service-based options for employees including management will vest on a four-year time-based vesting schedule.

Under

the 2022 Equity Plan, annual service options for members of the Board of Directors will vest entirely after one year. Service Options are granted on a recurring basis. The Company granted Service Options, which were accounted for using the respective grant date fair value.

Immatics applied a Black-Scholes pricing model to estimate the fair value of the Service Options, with a weighted average fair value of $9.34 for Service Option granted during the six months ended June 30, 2024 and used the following weighted average assumptions:


	As of February 7, 2024			As of March 6, 2024			As of June 25, 2024
Exercise price in USD	$	11.15		$	12.31		$	12.00
Underlying share price in USD	$	11.15		$	12.31		$	12.00
Volatility		90.65	%		90.65	%		93.86	%
Time period (years)		6.11			6.11			5.50
Risk free rate		4.04	%		4.08	%		4.20	%
Dividend yield		0.00	%		0.00	%		0.00	%

Service Options outstanding as of June 30, 2024:


	2024
	Weighted average exercise price in USD		Number
Service Options outstanding on January 1		9.87		7,757,974
Service Options granted in 2024		12.19		1,275,900
Service Options forfeited		11.33		187,179
Service Options exercised		9.88		87,655
Service Options expired		9.88		54,407
Service Options outstanding on June 30		10.18		8,704,633
Service Options exercisable on June 30		10.11		3,833,364
Weighted average remaining contract life (years)		8.17

Performance-Based Options (“PSUs”)

In addition, after the closing of the ARYA Merger, certain executive officers and key personnel of the

Group

received under the 2020 Equity Plan performance-based options (“PSUs”), vesting based on both the achievement of market capitalization milestones and satisfaction of a four-year time-based vesting schedule. The PSUs are split into three equal tranches. The performance criteria for each of the three respective tranches requires Immatics to achieve a market capitalization of at least $1.5 billion, $2 billion and $3 billion, respectively.

The Company granted PSUs on February 7, 2024, which were accounted for by considering a weighted average fair value of $6.37. A Monte-Carlo simulation model has been used to measure the fair value at grant date of the PSUs. This model incorporates the impact of the performance criteria regarding market capitalization in the calculation of the award’s fair value at grant date. In addition to the probability of achieving the market capitalization performance criteria, the inputs used in the measurements of the fair value at grant date of the PSUs were as follows:


	As of February 7, 2024
Exercise price in USD	$	11.15
Underlying share price in USD	$	11.15
Volatility		77.62	%
Time period (years)		3.23
Risk-free rate		4.12	%
Dividend yield		0.00	%

PSUs outstanding as of June 30, 2024:


	2024
	Weighted average exercise price in USD		Number
PSUs outstanding on January 1		10.08		3,642,000
PSUs granted in 2024		11.15		50,000
PSUs forfeited		10.00		12,000
PSUs outstanding on June 30		10.09		3,680,000
PSUs exercisable on June 30		—		—
Weighted average remaining contract life (years)		6.10

The Group recognized total employee-related share-based compensation expenses from all plans, during the three and six months ended June 30, 2024 and 2023 as set out below:


	Three months ended June 30,						Six months ended June 30,
	2024			2023			2024			2023
	(Euros in thousands)						(Euros in thousands)
Research and development expenses		(2,595	)		(3,282	)		(4,863	)		(6,815	)
General and administrative expenses		(1,713	)		(2,231	)		(3,742	)		(4,800	)

Total		(4,308	)		(5,513	)		(8,605	)		(11,615	)

Provisions

6 Months Ended

Jun. 30, 2024

Provisions

11. Provisions

Provisions consist of the following:


	As of
	June 30, 2024		December 31, 2023
	(Euros in thousands)
Provision for bonuses		3,437		—

Total		3,437		—

These amounts include provisions for the Group’s annual employee bonuses.

Other current and non-current assets (Tables)

6 Months Ended

Jun. 30, 2024

Summary of Other current assets

Other current assets consist of the following:


	As of
	June 30, 2024		December 31, 2023
	(Euros in thousands)
Prepaid expenses		12,370		10,619
Value added tax receivables		803		1,644
Other assets		12,027		7,119

Total		25,200		19,382

Summary of Other non-current assets

Other

non-current

assets consist of the following:


	As of
	June 30, 2024		December 31, 2023
	(Euros in thousands)
Prepaid expenses		589		1,414
Other assets		747		603

Total		1,336		2,017

Events occurring after the reporting period	6 Months Ended
Events occurring after the reporting period	Jun. 30, 2024
Text Block [Abstract]
Events occurring after the reporting period	19. Events occurring after the interim reporting period The Company evaluated further subsequent events for recognition or disclosure through August 13, 2024 and did not identify additional material subsequent events.

Share-based payments - Summary of Options Granted Priced Using Black Scholes for SARs, Tandem Awards, Converted Options, Matching Stock Options and Monte Carlo Option Pricing Model (Detail)	Jun. 25, 2024 yr $ / shares	Mar. 06, 2024 yr $ / shares	Feb. 07, 2024 yr $ / shares
Additional Grants Under 2020 and 2022 Plan [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price	$ 12	$ 12.31	$ 11.15
Underlying share price	$ 12	$ 12.31	$ 11.15
Volatility	93.86%	90.65%	90.65%
Time period (years) \| yr	5.5	6.11	6.11
Risk free rate	4.20%	4.08%	4.04%
Dividend yield	0.00%	0.00%	0.00%
Performance Based Options [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price			$ 11.15
Underlying share price			$ 11.15
Volatility			77.62%
Time period (years) \| yr			3.23
Risk free rate			4.12%
Dividend yield			0.00%

Income Tax - Additional Information (Detail) - EUR (€) € in Millions	3 Months Ended			6 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Statements [Line Items]
Statutory tax rate	30.40%		30.40%	30.40%	30.40%
Corporate income tax rate	21.00%		21.00%	21.00%	21.00%
GERMANY \| Immatics Biotechnologies GmbH [Member]
Statements [Line Items]
Percentage Of Income That Can Be Used To Set Off Tax Losses Carry Forward				70.00%
Percentage Of Pretax Income Subject To Income Tax				30.00%
Percentage of income that is eligible to be set off with tax losses in respect of trade tax				60.00%
Percentage of pre tax income subject to trade tax				40.00%
BMS And Moderna Collaboration Agreement [Member]
Statements [Line Items]
Current income tax expense income	€ 0.2
Genmab Collaboration Agreement [Member]
Statements [Line Items]
Current income tax expense income				€ 1.5
Amount of revenue that was included in the balance of contract at the beginning of the period		€ 14.9		€ 14.9

Significant events and changes in the current reporting period - Additional Information (Detail) € in Thousands		6 Months Ended
	Jan. 22, 2024 EUR (€) shares	Jun. 30, 2024 EUR (€)	Jun. 30, 2023 EUR (€)	Jan. 22, 2024 $ / shares
Disclosure Of ChangesIn Accounting Policies Accounting Estimates And Errors [Line Items]
Issue Of Share Capital Net Of Transaction Costs		€ 173,440	€ 37,411
Issued capital [member]
Disclosure Of ChangesIn Accounting Policies Accounting Estimates And Errors [Line Items]
Issue Of Share Capital Net Of Transaction Costs		183	37
Share premium [member]
Disclosure Of ChangesIn Accounting Policies Accounting Estimates And Errors [Line Items]
Issue Of Share Capital Net Of Transaction Costs		€ 173,257	€ 37,374
Public Offering [Member]
Disclosure Of ChangesIn Accounting Policies Accounting Estimates And Errors [Line Items]
Gross Proceeds From Initial Public Offer	€ 185,000
Payments for share issue costs	11,500
Public Offering [Member] \| Issued capital [member]
Disclosure Of ChangesIn Accounting Policies Accounting Estimates And Errors [Line Items]
Issue Of Share Capital Net Of Transaction Costs	183
Public Offering [Member] \| Share premium [member]
Disclosure Of ChangesIn Accounting Policies Accounting Estimates And Errors [Line Items]
Issue Of Share Capital Net Of Transaction Costs	€ 173,300
Public Offering [Member] \| Major ordinary share transactions [member]
Disclosure Of ChangesIn Accounting Policies Accounting Estimates And Errors [Line Items]
Increase (decrease) in number of ordinary shares issued \| shares	18,313,750
Sale Of Stock Issue Price Per Share \| $ / shares				$ 11

Other current liabilities - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2024
Non Interest Bearing Liability [Member]
Disclosure of detailed information about other current liabilities [Line Items]
Borrowings maturity	one year

Significant accounting policies (Policies)	6 Months Ended
Significant accounting policies (Policies)	Jun. 30, 2024
Text Block [Abstract]
Basis of presentation	Basis of presentation The unaudited interim condensed consolidated financial statements of the Group as of June 30, 2024 and for the three and six months ended June 30, 2024 and 2023 have been prepared on a going concern basis in accordance with International Accounting Standard 34 (“Interim Financial Reporting”), as issued by the International Accounting Standards Board (“IASB”) and have not been audited by a statutory auditor. In accordance with IAS 34, the unaudited interim condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements and should be read in conjunction with the Group’s annual financial statements for the year ended December 31, 2023, which have been prepared in accordance with IFRS ® Accounting Standards as issued by the International Accounting Standards Board (“IASB”), taking into account the recommendations of the IFRS Interpretations Committee (“IFRIC ® Interpretations”). In these notes to the unaudited condensed consolidated financial statements, information is provided primarily on the items for which there have been significant changes compared with the consolidated financial statements of the Group for fiscal year 2023. The unaudited interim condensed consolidated financial statements are presented in Euros, which is the functional and reporting currency of the parent, Immatics N.V. Assets and liabilities of foreign operations are translated into Euros at the rate of exchange prevailing at the reporting date. The unaudited interim condensed consolidated statement of loss is translated at average exchange rates. The currency translation differences are recognized in other comprehensive income. The accounting policies adopted in the preparation of the unaudited interim condensed consolidated financial statements are consistent with those followed in the preparation of the Group’s annual consolidated financial statements for the year ended December 31, 2023. The new and amended standards and interpretations applicable for the first time as of January 1, 2024, as disclosed in the notes to the consolidated financial statements for the year ended December 31, 2023, had no impact on the unaudited interim condensed consolidated financial statements of the Group for the three and six months ended June 30, 2024. In April 2024, IFRS 18, “Presentation and Disclosure in Financial Statements” was issued to achieve comparability of the financial performance of similar entities. The standard, which replaces IAS 1 “Presentation of Financial Statements”, impacts the presentation of primary financial statements and notes, including the statement of earnings where companies will be required to present separate categories of income and expense for operating, investing, and financing activities with prescribed subtotals for each new category. The standard will also require management-defined performance measures to be explained and included in a separate note within the consolidated financial statements. The standard is effective for annual reporting periods beginning on or after January 1, 2027, including interim financial statements, and requires retrospective application. The Company is currently assessing the impact of the new standard. Estimates and assumptions have to be made in the unaudited interim consolidated financial statements as of June 30, 2024. These have an impact on the amounts and disclosures of the recognized assets and liabilities, income and expenses, and contingent liabilities. The estimates and judgments are essentially unchanged from the circumstances described in the consolidated financial statements of the Group for the fiscal year 2023. New developments may result in amounts deviating from the original estimates. These possible developments are outside the sphere of influence of the management.

Accounts payable - Summary of Accounts Payable (Detail) - EUR (€) € in Thousands	Jun. 30, 2024	Dec. 31, 2023
Trade and other current payables [abstract]
Accounts payables	€ 3,800	€ 7,666
Accrued liabilities	14,991	17,540
Total	€ 18,791	€ 25,206

Share-based payments (Tables)

6 Months Ended

Jun. 30, 2024

Summary of Employee Related Share Based Compensation Expense

The Group recognized total employee-related share-based compensation expenses from all plans, during the three and six months ended June 30, 2024 and 2023 as set out below:


	Three months ended June 30,						Six months ended June 30,
	2024			2023			2024			2023
	(Euros in thousands)						(Euros in thousands)
Research and development expenses		(2,595	)		(3,282	)		(4,863	)		(6,815	)
General and administrative expenses		(1,713	)		(2,231	)		(3,742	)		(4,800	)

Total		(4,308	)		(5,513	)		(8,605	)		(11,615	)

Matching Stock Options [Member]

Converted Options [Member]

Matching Stock Options outstanding as of June 30, 2024:


	2024
	Weighted average exercise price in USD		Number
Matching Stock Options outstanding on January 1		10.00		1,342,648
Matching Stock Options forfeited		—		—
Matching Stock Options exercised		10.00		21,748
Matching Stock Options expired		—		—
Matching Stock Options outstanding on June 30		10.00		1,320,900
Matching Stock Options exercisable on June 30		10.00		1,320,900
Weighted average remaining contract life (years)		6.00

Additional Grants Under 2020 Plan [Member]

Converted Options outstanding as of June 30, 2024:


	2024
	Weighted average exercise price in USD		Number
Converted Options outstanding on January 1		2.81		503,310
Converted Options forfeited		—		—
Converted Options exercised		1.22		23,207
Converted Options expired		—		—
Converted Options outstanding on June 30		2.89		480,103
Converted Options exercisable on June 30		2.89		480,103
Weighted average remaining contract life (years)		3.51

Summary of Options Granted Priced Using Black Scholes for SARs, Tandem Awards, Converted Options, Matching Stock Options and Monte Carlo Option Pricing Model

Immatics applied a Black-Scholes pricing model to estimate the fair value of the Service Options


	As of February 7, 2024			As of March 6, 2024			As of June 25, 2024
Exercise price in USD	$	11.15		$	12.31		$	12.00
Underlying share price in USD	$	11.15		$	12.31		$	12.00
Volatility		90.65	%		90.65	%		93.86	%
Time period (years)		6.11			6.11			5.50
Risk free rate		4.04	%		4.08	%		4.20	%
Dividend yield		0.00	%		0.00	%		0.00	%

Performance Based Options [Member]

Service Options outstanding as of June 30, 2024:


	2024
	Weighted average exercise price in USD		Number
Service Options outstanding on January 1		9.87		7,757,974
Service Options granted in 2024		12.19		1,275,900
Service Options forfeited		11.33		187,179
Service Options exercised		9.88		87,655
Service Options expired		9.88		54,407
Service Options outstanding on June 30		10.18		8,704,633
Service Options exercisable on June 30		10.11		3,833,364
Weighted average remaining contract life (years)		8.17

Summary of Options Granted Priced Using Black Scholes for SARs, Tandem Awards, Converted Options, Matching Stock Options and Monte Carlo Option Pricing Model

In addition to the probability of achieving the market capitalization performance criteria, the inputs used in the measurements of the fair value at grant date of the PSUs were as follows:


	As of February 7, 2024
Exercise price in USD	$	11.15
Underlying share price in USD	$	11.15
Volatility		77.62	%
Time period (years)		3.23
Risk-free rate		4.12	%
Dividend yield		0.00	%

PSUs outstanding as of June 30, 2024:


	2024
	Weighted average exercise price in USD		Number
PSUs outstanding on January 1		10.08		3,642,000
PSUs granted in 2024		11.15		50,000
PSUs forfeited		10.00		12,000
PSUs outstanding on June 30		10.09		3,680,000
PSUs exercisable on June 30		—		—
Weighted average remaining contract life (years)		6.10

Other current liabilities (Tables)

6 Months Ended

Jun. 30, 2024

Summary of other current liabilities

Other current liabilities consist of the following:


	As of
	June 30, 2024		December 31, 2023
	(Euros in thousands)
Income tax liability		5,129		4,298
Accrual for vacation and overtime		2,183		1,277
Payroll tax		780		3,560
Other liabilities		1,929		213

Total		10,021		9,348

Revenue from collaboration agreements (Tables)

6 Months Ended

Jun. 30, 2024

Summary of Deferred revenue related to the collaboration agreements

Deferred revenue related to the collaboration agreements consists of the following:


	As of
	June 30, 2024		December 31, 2023
	(Euros in thousands)
Current		95,521		100,401
Non-current		75,298		115,527

Total		170,819		215,928

Summary of revenue from collaboration agreements explanatory

Revenue from collaboration agreements was realized with the following partners:


	Three months ended June 30,				Six months ended June 30,
	2024		2023		2024		2023
	(Euros in thousands)				(Euros in thousands)
BMS, United States		10,035		21,439		15,770		31,935
Moderna, United States		8,720		—		18,303		—
Genmab, Denmark		—		915		14,951		215

Total		18,755		22,354		49,024		32,150

Financial Instruments

6 Months Ended

Jun. 30, 2024

Financial Instruments

16. Financial Instruments

Set out below are the carrying amounts and fair values of the Group’s financial instruments that are carried in the unaudited interim condensed consolidated financial statements.


	Carrying amount per measurement category
	Financial assets				Financial liabilities
(Euros in thousands)	At fair value through profit and loss		At amortized cost		At fair value through profit and loss		At amortized cost		IFRS 16		June 30, 2024
Current/non-current assets
Cash and cash equivalents		—		158,143		—		—		—		158,143
Short-term deposits*		—		372,964		—		—		—		372,964
Accounts receivables		—		2,811		—		—		—		2,811
Other current/non-current assets*		—		8,187		—		—		—		8,187
Current/non-current liabilities
Accounts payables		—		—		—		18,791		—		18,791
Other current liabilities		—		—		—		50		—		50
Liabilities for warrants		—		—		18,598		—		—		18,598
Lease liabilities		—		—		—		—		17,413		17,413

Total		—		542,105		18,598		18,841		17,413		—


	Carrying amount per measurement category
	Financial assets				Financial liabilities
(Euros in thousands)	At fair value through profit and loss		At amortized cost		At fair value through profit and loss		At amortized cost		IFRS 16		December 31, 2023
Current/non-current assets
Cash and cash equivalents		—		218,472		—		—		—		218,472
Short-term deposits*		—		207,423		—		—		—		207,423
Accounts receivables		—		4,093		—		—		—		4,093
Other current/non-current assets*		—		4,552		—		—		—		4,552
Current/non-current liabilities
Accounts payables		—		—		—		24,280		—		24,280
Other current liabilities		—		—		—		50		—		50
Liabilities for warrants		—		—		18,993		—		—		18,993
Lease liabilities		—		—		—		—		15,402		15,402

Total		—		434,540		18,993		24,330		15,402		—

*	“Short-term deposits” are classified within the balance sheet item “Other financial assets”. Other current/non-current assets comprise mainly of accrued interest and deposits.

The book value of financial assets and liabilities other than lease liabilities and liabilities for warrants represent a reasonable approximation of the fair value.

Liabilities for warrants are comprised of the Immatics Warrants issued to investors with a cashless exercise mechanism as a current liability which the Company accounted for according to provisions of IAS 32. The Company measures the warrants at fair value by using the closing price of warrants at Nasdaq. The warrants are measured in each reporting period. Changes in the fair value are recognized in the Company’s Consolidated Statement of Loss as financial income or expenses, as appropriate. The warrants are classified as Level 1 of the fair value hierarchy. The maturity of the liabilities for warrants is dependent on the development of the share price as well as the decisions by the Immatics Warrants holders.

Commitments and contingencies	6 Months Ended
Commitments and contingencies	Jun. 30, 2024
Text Block [Abstract]
Commitments and contingencies	18. Commitments and contingencies The statements regarding contingent liabilities and other financial liabilities described in the consolidated financial statements of the Group for the fiscal year 2023 are essentially unchanged.

Condensed Consolidated Statement of Changes in Shareholders' equity of Immatics N.V. - EUR (€) € in Thousands	Total	Share capital [member]	Share premium [member]	Accumulated deficit [member]	Other reserves [member]
Balance as of January 1 at Dec. 31, 2022	€ 213,164	€ 767	€ 714,177	€ (500,299)	€ (1,481)
Other comprehensive income	340				340
Net loss	(44,357)			(44,357)
Comprehensive loss for the year	(44,017)			(44,357)	340
Equity-settled share-based compensation	11,615		11,615
Share options exercised	40		40
Issue of share capital – net of transaction costs	37,411	37	37,374
Balance as of June 30 at Jun. 30, 2023	218,213	804	763,206	(544,656)	(1,141)
Balance as of January 1 at Dec. 31, 2023	225,084	847	823,166	(597,293)	(1,636)
Other comprehensive income	798				798
Net loss	(21,076)			(21,076)
Comprehensive loss for the year	(20,278)			(21,076)	798
Equity-settled share-based compensation	8,605		8,605
Share options exercised	1,037	1	1,036
Issue of share capital – net of transaction costs	173,440	183	173,257
Balance as of June 30 at Jun. 30, 2024	€ 387,888	€ 1,031	€ 1,006,064	€ (618,369)	€ (838)

The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.

+ References + Details

The amount of residual interest in the assets of the entity after deducting all its liabilities.

+ References + Details

The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]

+ References

+ Details

Condensed Consolidated Statement of Comprehensive Loss of Immatics N.V. - EUR (€) € in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Statement of comprehensive income [abstract]
Net loss	€ (18,022)	€ (24,610)	€ (21,076)	€ (44,357)
Items that may be reclassified subsequently to profit or loss
Currency translation differences from foreign operations	462	(224)	798	340
Total comprehensive loss for the year	€ (17,560)	€ (24,834)	€ (20,278)	€ (44,017)

The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.

+ References + Details

The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]

+ References

+ Details

Other current liabilities

6 Months Ended

Jun. 30, 2024

Other current liabilities

13. Other current liabilities

Other current liabilities consist of the following:


	As of
	June 30, 2024		December 31, 2023
	(Euros in thousands)
Income tax liability		5,129		4,298
Accrual for vacation and overtime		2,183		1,277
Payroll tax		780		3,560
Other liabilities		1,929		213

Total		10,021		9,348

Other current liabilities are

non-interest-bearing

and are due within one year. The carrying amounts of other current liabilities represent fair values due to their short-term nature.

Other current and non-current assets

6 Months Ended

Jun. 30, 2024

Other current and non-current assets

9. Other current and

non-current

assets

Other current assets consist of the following:


	As of
	June 30, 2024		December 31, 2023
	(Euros in thousands)
Prepaid expenses		12,370		10,619
Value added tax receivables		803		1,644
Other assets		12,027		7,119

Total		25,200		19,382

Prepaid expenses include expenses for licenses and software of €6.8 million as of June 30, 2024 and €7.0 million as of December 31, 2023 and prepaid maintenance expenses of €1.2 million as of June, 2024 and €0.9 million as of December 31, 2023. The Group accrued €0.1 million as of June 30, 2024 and €0.2 million as of December 31, 2023 of incremental cost for the successful arrangement of the BMS collaboration signed in 2019.

The remaining amount is mainly related to prepaid expenses for insurance, contract research organizations and travel expenses.

Other assets include accrued interest income related to short-term deposits of €7.0 million as of June 30, 2024 and €2.6 million as of December 31, 2023 and receivables from capital gains tax of €4.5 million as of June 30, 2024 and €3.1 million as of December 31, 2023.

Other

non-current

assets consist of the following:


	As of
	June 30, 2024		December 31, 2023
	(Euros in thousands)
Prepaid expenses		589		1,414
Other assets		747		603

Total		1,336		2,017

Prepaid expenses include the

non-current

portion of prepayments for licensing agreements of €0.1 million as of June 30, 2024 and €0.5 million as of December 31, 2023, prepaid maintenance expenses of €0.3 million as of June 30, 2024 and €0.5 million as of December 31, 2023 and accrued incremental cost of the BMS collaboration agreement of €0.2 million as of June 30, 2024 and €0.4 million as of December 31, 2023. Other assets include the

non-current

portion

for prepaid deposit expenses.

Condensed Consolidated Statement of Loss of Immatics N.V. € in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024 EUR (€) € / shares	Jun. 30, 2023 EUR (€) € / shares	Jun. 30, 2024 EUR (€) € / shares	Jun. 30, 2023 EUR (€) € / shares
Profit or loss [abstract]
Revenue from collaboration agreements	€ 18,755	€ 22,354	€ 49,024	€ 32,150
Research and development expenses	(35,216)	(27,317)	(67,324)	(54,898)
General and administrative expenses	(10,128)	(9,358)	(21,770)	(18,944)
Other income	25	6	37	948
Operating result	(26,564)	(14,315)	(40,033)	(40,744)
Change in fair value of liabilities for warrants	(648)	(13,105)	395	(5,708)
Other financial income	9,665	3,954	20,580	6,748
Other financial expenses	(305)	(1,144)	(515)	(4,653)
Financial result	8,712	(10,295)	20,460	(3,613)
Loss before taxes	(17,852)	(24,610)	(19,573)	(44,357)
Taxes on income	(170)	0	(1,503)	0
Net loss	€ (18,022)	€ (24,610)	€ (21,076)	€ (44,357)
Net loss per share:
Basic \| € / shares	€ (0.17)	€ (0.32)	€ (0.21)	€ (0.58)
Diluted \| € / shares	€ (0.17)	€ (0.32)	€ (0.21)	€ (0.58)

Other current liabilities - Summary of other current liabilities (Detail) - EUR (€) € in Thousands	Jun. 30, 2024	Dec. 31, 2023
Disclosure of detailed information about other current liabilities [Line Items]
Income tax liability	€ 5,129	€ 4,298
Accrual for vacation and overtime	2,183	1,277
Payroll tax	780	3,560
Other liabilities	1,929	213
Total	€ 10,021	€ 9,348

Shareholders' equity - Additional Information (Detail) € / shares in Units, € in Thousands		6 Months Ended
	Jan. 22, 2024 EUR (€)	Jun. 30, 2024 EUR (€) € / shares shares	Jan. 22, 2024 $ / shares shares	Dec. 31, 2023 shares
Registered Direct Offering [Member]
Disclosure of classes of share capital [line items]
Number of shares \| shares			18,313,750
Share issue related cost	€ 11,500
Issue of equity	185,000
Share Issued Price per Share \| $ / shares			$ 11
Issued capital [Member] \| Registered Direct Offering [Member]
Disclosure of classes of share capital [line items]
Issue of equity	183
Share premium [Member] \| Registered Direct Offering [Member]
Disclosure of classes of share capital [line items]
Issue of equity	€ 173,300
Reorganization [Member]
Disclosure of classes of share capital [line items]
Number of shares outstanding \| shares		103,105,906		84,657,789
Par value per share \| € / shares		€ 0.01
Ordinary Shares [Member] \| Issued capital [Member]
Disclosure of classes of share capital [line items]
Issue of equity		€ 1
Ordinary Shares [Member] \| Share premium [Member]
Disclosure of classes of share capital [line items]
Issue of equity		€ 1,000

Other current and non-current assets - Summary of Other non-current assets (Detail) - EUR (€) € in Thousands	Jun. 30, 2024	Dec. 31, 2023
Trade and other non-current receivables [abstract]
Prepaid expenses	€ 589	€ 1,414
Other assets	747	603
Total	€ 1,336	€ 2,017

Financial result

6 Months Ended

Jun. 30, 2024

Financial result

6. Financial result

Financial income and financial expenses consist of the following:


	Three months ended June 30,						Six months ended June 30,
	2024			2023			2024			2023
	(Euros in thousands)						(Euros in thousands)
Change in fair value of liabilities for warrants		(648	)		(13,105	)		395			(5,708	)

Interest income		6,366			2,744			12,659			4,999
Foreign currency gains		2,763			1,210			7,851			1,749
Gain on other financial instruments		536			—			70			—

Other financial income		9,665			3,954			20,580			6,748

Interest expenses		(226	)		(206	)		(420	)		(401	)
Foreign currency losses		(79	)		(805	)		(95	)		(4,119	)
Losses on financial instruments		—			(133	)		—			(133	)

Other financial expenses		(305	)		(1,144	)		(515	)		(4,653	)
Financial result		8,712			(10,295	)		20,460			(3,613	)

The fair value of the warrants decreased from €2.64 ($2.92) per warrant as of December 31, 2023 to €2.50 ($2.70) per warrant as of March 31, 2024 and increased to €2.59 ($2.77) as of June 30, 2024. The result is an increase in fair value of liabilities for warrants of €0.6 million and a corresponding expense for the three months ended June 30, 2024 and a decrease in fair value of liabilities for warrants of €0.4 million for the six months ended June 30, 2024.

The fair value of the warrants decreased from €

2.35

2.51

) per warrant as of December 31, 2022 to €1.32 ($1.44) per warrant as of March 31, 2023 and increased to €3.15 ($3.42) as of June 30, 2023. The result is an increase in fair value of liabilities for warrants of €13.1 million for the three months ended June 30, 2023 and an increase in fair value of liabilities for warrants of €5.7 million for the six months ended June 30, 2023.

Interest income mainly results from short-term deposits as well as cash balances. Interest expenses mainly result from leases.

Foreign currency gains and losses mainly consist of realized and unrealized gains and losses in connection with our USD holdings of cash and cash equivalents and short-term deposits

Immatics N.V. and Immatics GmbH.

Losses and gains on financial instruments include expected credit losses on cash and cash equivalents and Other financial assets for the three and six months ended June 30, 2024 and 2023.

Significant accounting policies	6 Months Ended
Significant accounting policies	Jun. 30, 2024
Text Block [Abstract]
Disclosure of changes in accounting policies [text block]	3. Significant accounting policies Basis of presentation The unaudited interim condensed consolidated financial statements of the Group as of June 30, 2024 and for the three and six months ended June 30, 2024 and 2023 have been prepared on a going concern basis in accordance with International Accounting Standard 34 (“Interim Financial Reporting”), as issued by the International Accounting Standards Board (“IASB”) and have not been audited by a statutory auditor. In accordance with IAS 34, the unaudited interim condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements and should be read in conjunction with the Group’s annual financial statements for the year ended December 31, 2023, which have been prepared in accordance with IFRS ® Accounting Standards as issued by the International Accounting Standards Board (“IASB”), taking into account the recommendations of the IFRS Interpretations Committee (“IFRIC ® Interpretations”). In these notes to the unaudited condensed consolidated financial statements, information is provided primarily on the items for which there have been significant changes compared with the consolidated financial statements of the Group for fiscal year 2023. The unaudited interim condensed consolidated financial statements are presented in Euros, which is the functional and reporting currency of the parent, Immatics N.V. Assets and liabilities of foreign operations are translated into Euros at the rate of exchange prevailing at the reporting date. The unaudited interim condensed consolidated statement of loss is translated at average exchange rates. The currency translation differences are recognized in other comprehensive income. The accounting policies adopted in the preparation of the unaudited interim condensed consolidated financial statements are consistent with those followed in the preparation of the Group’s annual consolidated financial statements for the year ended December 31, 2023. The new and amended standards and interpretations applicable for the first time as of January 1, 2024, as disclosed in the notes to the consolidated financial statements for the year ended December 31, 2023, had no impact on the unaudited interim condensed consolidated financial statements of the Group for the three and six months ended June 30, 2024. In April 2024, IFRS 18, “Presentation and Disclosure in Financial Statements” was issued to achieve comparability of the financial performance of similar entities. The standard, which replaces IAS 1 “Presentation of Financial Statements”, impacts the presentation of primary financial statements and notes, including the statement of earnings where companies will be required to present separate categories of income and expense for operating, investing, and financing activities with prescribed subtotals for each new category. The standard will also require management-defined performance measures to be explained and included in a separate note within the consolidated financial statements. The standard is effective for annual reporting periods beginning on or after January 1, 2027, including interim financial statements, and requires retrospective application. The Company is currently assessing the impact of the new standard. Estimates and assumptions have to be made in the unaudited interim consolidated financial statements as of June 30, 2024. These have an impact on the amounts and disclosures of the recognized assets and liabilities, income and expenses, and contingent liabilities. The estimates and judgments are essentially unchanged from the circumstances described in the consolidated financial statements of the Group for the fiscal year 2023. New developments may result in amounts deviating from the original estimates. These possible developments are outside the sphere of influence of the management.

Related party disclosures	6 Months Ended
Related party disclosures	Jun. 30, 2024
Text Block [Abstract]
Related party disclosures	15. Related party disclosures During the three and six months ended June 30, 2024, the Group did not enter into any new related-party transactions with its key management personnel or with related entities other than the granting of a total of 280,000 Service options to its Board of Directors for the three and six months ended June 30, 2024.

Other current and non-current assets -Summary of Other current assets (Detail) - EUR (€) € in Thousands	Jun. 30, 2024	Dec. 31, 2023
Trade and other receivables [abstract]
Prepaid expenses	€ 12,370	€ 10,619
Value added tax receivables	803	1,644
Other assets	12,027	7,119
Total	€ 25,200	€ 19,382

Property, plant and equipment, intangible assets and Right-of-use assets - Additional Information (Detail) - EUR (€) € in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Statements [Line Items]
Purchase of property, plant and equipment	€ 2.2	€ 11.6	€ 9.7	€ 15.7
Office Equipment And Installations [Member]
Statements [Line Items]
Purchase of property, plant and equipment			€ 6.3
Rental Land [Member]
Statements [Line Items]
Addition to right-of-use assets	2.4
Right of use assets modification increase	€ 1.2

Group information	6 Months Ended
Group information	Jun. 30, 2024
Text Block [Abstract]
Group information	1. Group information Immatics N.V., together with its German subsidiary Immatics Biotechnologies GmbH and its U.S. subsidiary, Immatics US Inc., (“Immatics” or “the Group”) is a biotechnology group that is primarily engaged in the research and development of T cell redirecting immunotherapies for the treatment of cancer. Immatics N.V., a Dutch public limited liability company, was converted on July 1, 2020 from Immatics B.V., a Dutch company with limited liability. Immatics Biotechnologies GmbH (“Immatics GmbH”) and Immatics US Inc. became wholly-owned subsidiaries of Immatics N.V. as part of the ARYA Merger on July 1, 2020. Immatics N.V. is registered with the commercial register at the Netherlands Chamber of Commerce under RSIN 861058926 with a corporate seat in Amsterdam and is located at Paul-Ehrlich Str. 15 in 72076 Tübingen, Germany. Prior to July 1, 2020, Immatics N.V. was a shell company with no active trade or business or subsidiaries and all relevant assets and liabilities as well as income and expenses were borne by Immatics Biotechnologies GmbH and its U.S. subsidiary Immatics US, Inc. Immatics N.V. is the ultimate parent company of the Group. These unaudited interim condensed consolidated financial statements of the Group for the three and six months ended June 30, 2024, were authorized for issue by the Audit Committee of Immatics N.V. on August 13, 2024.

Provisions (Tables)

6 Months Ended

Jun. 30, 2024

Summary of provisions

Provisions consist of the following:


	As of
	June 30, 2024		December 31, 2023
	(Euros in thousands)
Provision for bonuses		3,437		—

Total		3,437		—

Financial Instruments - Summary of Carrying Amounts and Fair values of Group's Financial Instruments (Detail) - EUR (€) € in Thousands	Jun. 30, 2024	Dec. 31, 2023
Disclosure of detailed information about financial instruments [line items]
Financial assets and Financial liabilities	€ 0	€ 0
At cost or in accordance with IFRS 16 within fair value model [Member]
Disclosure of detailed information about financial instruments [line items]
Financial liabilities, Carrying amount	17,413	15,402
Cash and cash equivalents [Member]
Disclosure of detailed information about financial instruments [line items]
Financial assets and Financial liabilities	158,143	218,472
Short-Term Deposits [Member]
Disclosure of detailed information about financial instruments [line items]
Financial assets and Financial liabilities	372,964	207,423
Accounts receivables [Member]
Disclosure of detailed information about financial instruments [line items]
Financial assets and Financial liabilities	2,811	4,093
Other current/non-current assets [Member]
Disclosure of detailed information about financial instruments [line items]
Financial assets and Financial liabilities	8,187	4,552
Accounts payables [Member]
Disclosure of detailed information about financial instruments [line items]
Financial assets and Financial liabilities	18,791	24,280
Other current liabilities [Member]
Disclosure of detailed information about financial instruments [line items]
Financial assets and Financial liabilities	50	50
Liabilities for warrants [Member]
Disclosure of detailed information about financial instruments [line items]
Financial assets and Financial liabilities	18,598	18,993
Lease liabilities [Member]
Disclosure of detailed information about financial instruments [line items]
Financial assets and Financial liabilities	17,413	15,402
Lease liabilities [Member] \| At cost or in accordance with IFRS 16 within fair value model [Member]
Disclosure of detailed information about financial instruments [line items]
Financial liabilities, Carrying amount	17,413	15,402
Financial liabilities at fair value through profit or loss, category [Member]
Disclosure of detailed information about financial instruments [line items]
Financial liabilities, Carrying amount	18,598	18,993
Financial liabilities at fair value through profit or loss, category [Member] \| Liabilities for warrants [Member]
Disclosure of detailed information about financial instruments [line items]
Financial liabilities, Carrying amount	18,598	18,993
Financial liabilities at amortised cost, category [Member]
Disclosure of detailed information about financial instruments [line items]
Financial liabilities, Carrying amount	18,841	24,330
Financial liabilities at amortised cost, category [Member] \| Accounts payables [Member]
Disclosure of detailed information about financial instruments [line items]
Financial liabilities, Carrying amount	18,791	24,280
Financial liabilities at amortised cost, category [Member] \| Other current liabilities [Member]
Disclosure of detailed information about financial instruments [line items]
Financial liabilities, Carrying amount	50	50
Financial liabilities at amortised cost, category [Member] \| Lease liabilities [Member]
Disclosure of detailed information about financial instruments [line items]
Financial liabilities, Carrying amount	0	0
Financial assets at amortised cost, category [Member]
Disclosure of detailed information about financial instruments [line items]
Financial assets, Carrying amount	542,105	434,540
Financial assets at amortised cost, category [Member] \| Cash and cash equivalents [Member]
Disclosure of detailed information about financial instruments [line items]
Financial assets, Carrying amount	158,143	218,472
Financial assets at amortised cost, category [Member] \| Short-Term Deposits [Member]
Disclosure of detailed information about financial instruments [line items]
Financial assets, Carrying amount	372,964	207,423
Financial assets at amortised cost, category [Member] \| Accounts receivables [Member]
Disclosure of detailed information about financial instruments [line items]
Financial assets, Carrying amount	2,811	4,093
Financial assets at amortised cost, category [Member] \| Other current/non-current assets [Member]
Disclosure of detailed information about financial instruments [line items]
Financial assets, Carrying amount	€ 8,187	€ 4,552

Shareholders' equity	6 Months Ended
Shareholders' equity	Jun. 30, 2024
Text Block [Abstract]
Shareholders' equity	14. Shareholders’ equity As of June 30, 2024 and December 31, 2023, the total number of ordinary shares of Immatics N.V. outstanding is 103,105,906 and 84,657,789 with a par value of €0.01, respectively. On January 22, 2024, the Group closed an offering of 18,313,750 ordinary shares with a public offering price of $11.00 per ordinary share. The Group received gross proceeds of €185.0 million less transaction costs of €11.5 million, resulting in an increase in share capital of €183 thousand and share premium of €173.3 million. Additionally, the number of ordinary shares increased during the three and six months ended June 30, 2024, due to exercised share options from the Group’s equity incentive plan, resulting in an increase in share capital of €1 thousand and share premium of € 1.0 million. Other reserves are related to accumulated foreign currency translation amounts associated with the Group’s U.S. operations.

Related party disclosures - Additional Information (Detail) - shares	3 Months Ended	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2024
Board of Directors Chairman [Member]
Disclosure of transactions between related parties [line items]
Related party transaction options granted	280,000	280,000

Revenue from collaboration agreements - Additional Information (Detail) - EUR (€) € in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Disclosure Of Revenue From Contract With Customers [Line Items]
Amortization of contract costs capitalized				€ 400	€ 100
Receipt of upfront of payment	€ 18,755		€ 22,354	49,024	32,150
Genmab Collaboration Agreement [Member]
Disclosure Of Revenue From Contract With Customers [Line Items]
Amount of revenue that was included in the balance of contract at the beginning of the period		€ 14,900		14,900
Receipt of upfront of payment				14,900
BMS Collaboration Agreement [Member]
Disclosure Of Revenue From Contract With Customers [Line Items]
Proceeds from option exercise fee under collaborative arrangement			€ 13,700		€ 13,700
Collaboration Agreement [Member]
Disclosure Of Revenue From Contract With Customers [Line Items]
Milestone or royalty payment receivable	€ 0			€ 0

Group information - Additional Information (Detail)		3 Months Ended	6 Months Ended
Group information - Additional Information (Detail)	Aug. 13, 2024	Jun. 30, 2024	Jun. 30, 2024
Disclosure of non-adjusting events after reporting period [line items]
Date of end of reporting period		Jun. 30, 2024	Jun. 30, 2024
Authorization Of Financial Statements [Member]
Disclosure of non-adjusting events after reporting period [line items]
Date of authorisation for issue of financial statements	Aug. 13, 2024

Share-based payments - Summary of Employee Share Options (Detail)	6 Months Ended
	Jun. 30, 2024 shares $ / shares
Performance Based Options [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average exercise price, Outstanding at January 1, \| $ / shares	$ 10.08
SARs forfeited \| $ / shares	10
Weighted average exercise price, Outstanding at December 31, \| $ / shares	10.09
SARs exercisable \| $ / shares	$ 0
Number of share options, outstanding at January 1, \| shares	3,642,000
SARs forfeited \| shares	12,000
Number of share options, outstanding at December 31, \| shares	3,680,000
SARs exercisable \| shares	0
Weighted average remaining contract life (years)	6 years 1 month 6 days
Performance Based Options [Member] \| Granted On June 2024 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
SARs granted \| $ / shares	$ 11.15
SARs granted \| shares	50,000
Additional Grants Under 2020 and 2022 Plan [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average exercise price, Outstanding at January 1, \| $ / shares	$ 9.87
SARs forfeited \| $ / shares	11.33
SARs exercised \| $ / shares	9.88
SARs expired \| $ / shares	9.88
Weighted average exercise price, Outstanding at December 31, \| $ / shares	10.18
SARs exercisable \| $ / shares	$ 10.11
Number of share options, outstanding at January 1, \| shares	7,757,974
SARs forfeited \| shares	187,179
SARs exercised \| shares	87,655
SARs expired \| shares	54,407
Number of share options, outstanding at December 31, \| shares	8,704,633
SARs exercisable \| shares	3,833,364
Weighted average remaining contract life (years)	8 years 2 months 1 day
Additional Grants Under 2020 and 2022 Plan [Member] \| Granted On June 2024 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
SARs granted \| $ / shares	$ 12.19
SARs granted \| shares	1,275,900
Converted Options [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average exercise price, Outstanding at January 1, \| $ / shares	$ 2.81
SARs exercised \| $ / shares	1.22
SARs expired \| $ / shares	0
Weighted average exercise price, Outstanding at December 31, \| $ / shares	2.89
SARs exercisable \| $ / shares	$ 2.89
Number of share options, outstanding at January 1, \| shares	503,310
SARs exercised \| shares	23,207
SARs expired \| shares	0
Number of share options, outstanding at December 31, \| shares	480,103
SARs exercisable \| shares	480,103
Weighted average remaining contract life (years)	3 years 6 months 3 days
Converted Options [Member] \| Granted On June 2020 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
SARs forfeited \| $ / shares	$ 0
SARs forfeited \| shares	0
Matching Stock Options [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average exercise price, Outstanding at January 1, \| $ / shares	$ 10
SARs forfeited \| $ / shares	0
SARs exercised \| $ / shares	10
SARs expired \| $ / shares	0
Weighted average exercise price, Outstanding at December 31, \| $ / shares	10
SARs exercisable \| $ / shares	$ 10
Number of share options, outstanding at January 1, \| shares	1,342,648
SARs forfeited \| shares	0
SARs exercised \| shares	21,748
SARs expired \| shares	0
Number of share options, outstanding at December 31, \| shares	1,320,900
SARs exercisable \| shares	1,320,900
Weighted average remaining contract life (years)	6 years

Financial Instruments (Tables)

6 Months Ended

Jun. 30, 2024